Item 7.01 Regulation FD Disclosure ; AAR CORP.’s Vice President and Chief Financial Officer, Michael J. Sharp, presented at the KeyBanc Capital Markets Industrial, Automotive & Transportation Conference in Boston. ; Attached as Exhibit 99.1 are the slides used by Mr. Sharp in his presentation.
Exhibit Number, Exhibit Title or Description ; 23.1, Consent of Ernst & Young LLP, Avast plc’s independent auditors. ; 99.1, Management’s Discussion and Analysis of Financial Condition and Results of Operations of Avast. ; 99.2, Investor presentation, dated September 7, 2022. ; 99.3, Risks Related to the Avast plc Business. ; 99.4, Unaudited pro forma condensed combined financial information of NortonLifeLock Inc. giving effect to the acquisition of Avast plc, which includes the unaudited pro forma condensed combined statement of financial position as of July 1, 2022 and the unaudited pro forma condensed combined statement of comprehensive income for the year ended April 1, 2022 and the three months ended July 1, 2022, and the notes related thereto. ; 99.5, The historical audited consolidated financial statements and financial statement schedule of Avast plc as of and for each of the years ended December 31, 2021 and 2020, the notes related thereto and the related reports of Ernst & Young LLP, Avast plc’s independent auditors. ; 99.6, The historical unaudited condensed consolidated financial statements and financial statement schedule of Avast plc as of and for each of the six months ended June 30, 2022 and 2021, and the notes related thereto. ; 104, The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.
Item 7.01 Regulation FD Disclosure · AAR CORP.’s Vice President, Chief Financial Officer and Treasurer, Michael J. Sharp, presented at the Cowen and Company 37th Annual Aerospace/Defense & Transportation Conference on Thursday, February 4, 2016 in New York City. Attached as Exhibit 99.1 are the slides used by Mr. Sharp in his presentation. The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of t...
Disclaimer ; Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s expectations; beliefs; plans; strategies; investments; financial performance; expected benefits of new initiatives; content, products, experiences or service offerings (including timing and nature); priorities or performance; businesses and assets; future investments and crea...
EX-10.1 2 tm2217179d1_ex10-1.htm EXHIBIT 10.1 ; Exhibit 10.1 · Execution Version · SIXTH AMENDED AND RESTATED CREDIT AGREEMENT · dated as of May 27, 2022 · among · UNITED STATES STEEL CORPORATION · THE LENDERS PARTY HERETO · THE LC ISSUING BANKS PARTY HERETO and · JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent · JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A., WELLS FARGO BANK, NATIONAL ASSOCIATION, and · BARCLAYS BANK PLC, as Joint Lead Arrangers an...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 · SCHEDULE 14A · Definitive Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 · Filed by the Registrant ☒ · Filed by a Party other than the Registrant o · Check the appropriate box:
Item 1.01 Entry into a Material Definitive Agreement · On September 21, 2016, Hyperdynamics Corporation (“Hyperdynamics,” the “Company,” “we” or “us”), through its wholly-owned subsidiary, SCS Corporation (“SCS”) received an implementing Presidential Decree from the Republic of Guinea authorizing a Second Amendment (the “Second Amendment”) to the Hydrocarbon Production Sharing Contract, dated September 22, 2006, between SCS and the Republic of Guinea, as amended on Marc...
Delaware, 1-34392, 22-3672377 ; (State or other jurisdiction, (Commission File, (IRS Employer ; of incorporation), Number), Identification No.)
1., A copy of the Financial Institution Bond Standard Form No. 14, Bond No. FIB 0000609-11 in the amount of $900,000 (the “Fidelity Bond”); ; 2., A copy of the Secretary’s Certificate certifying the resolutions adopted by the Board of Directors, including all of the directors who are not interested persons, on July 21, 2008, approving the amount, type, form and coverage of the Fidelity Bond and including a statement as to the amount of the single insured bond that would have been obtained if the joint insured bond was not obtained and the period for which premiums for the Fidelity Bond have been paid; and ; 3., A copy of the agreement between the named insureds pursuant to Rule 17g-1(f).
SECURITIES AND EXCHANGE COMMISSION · Washington, D.C. 20549 · FORM 8-K · CURRENT REPORT · PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 · Date of Report (Date of Earliest Event Reported) – January 11, 2006 · WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter)